Anti-Human IL-17A (Ixekizumab)

Humanized antibody from mouse clone 2321

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2-8°C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ixekizumab.

Ixekizumab has similar binding affinity to and neutralization of human and cynomolgus monkey IL-17A as well as weak binding to rabbit IL-17A. No binding is detected against rat or mouse IL-17A.

IL-17 is a group of proinflammatory cytokines (IL-17A to IL-17F) released by T helper 17 (Th17) cells¹. IL-17A is the key effector cytokine of the group 1 and is involved in normal inflammatory and immune responses². Additionally, increased IL-17A plays an important role in the pathogenesis of ankylosing spondylitis (AS), a chronic autoimmune inflammatory disease that primarily affects the axial skeleton², and in the progression of psoriatic arthritis¹ and plaque psoriasis^{3, 4}.

Ixekizumab was developed as an IL-17A inhibitor for the treatment of AS, psoriasis, and psoriatic arthritis and has been approved for the treatment of some patients with plaque psoriasis³, psoriatic arthritis, AS, and non-radiographic axial spondyloarthritis⁴. Ixekizumab is a fully humanized monoclonal antibody that binds selectively to IL-17A and inhibits its interaction with the IL-17 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines^{2, 3}. Ixekizumab disrupts the proinflammatory cascade present in psoriasis⁴, resulting in decreased expression of cytokines from multiple T cell subsets as well as decreased keratinocyte proliferation and differentiation⁵.

IL-17A is expressed by Th17 cells, mast cells, and neutrophils.

Il-17R

1 Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537091/
2 Blair HA. Drugs. 79(4):433-443. 2019.
3 Markham A. Drugs. 76(8):901-905. 2016.
4 Preuss CV, Quick J. Ixekizumab. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431088/
5 Krueger JG, Fretzin S, Suárez-Fariñas M, et al. J Allergy Clin Immunol. 130(1):145-54.e9. 2012.
6 Genovese MC, Van den Bosch F, Roberson SA, et al. Arthritis Rheum. 62(4):929-939. 2010.
7 Wang CQF, Suárez-Fariñas M, Nograles KE, et al. J Invest Dermatol. 134(12):2990-2993. 214.
8 Beerli RR, Bauer M, Fritzer A, et al. MAbs. 6(6):1608-1620. 2014.
9 Clarke DO, Hilbish KG, Waters DG, et al. Reprod Toxicol. 58:160-173. 2015.